|Rat Target Sites||Mouse Target Sites||TD50 (mg/kg/day)|
|no test||no test||gal liv lun vsc||gal liv lun vsc||no test||1.37m,v|
|Hamster Target Sites||TD50
|gal liv||gal liv||5.8m|
Key to the Table Above
The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.
For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.
Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.
TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.
A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.
Chemical (Synonym) CAS # Species Sex Strain Route Xpo+Xpt PaperNum 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference or NCI/NTP:Site Path Site Path Notes TD50 DR Pval AuOp LoConf UpConf Cntrl 1 Inc 2 Inc 3 Inc Brkly Code
N-METHYL-N-FORMYLHYDRAZINE 758-17-8 3788 H f syg wat 24m24 716 0 10.6mg Toth;zkko,93,109-121;1979 --- mhs e 4.71mg P<.0005 + 2.73mg 8.73mg 0/13 24/31 liv mix e 11.3mg P<.0005 + 6.50mg 21.9mg 0/79 19/41 liv lcc e 25.1mg P<.0005 12.2mg 64.5mg 0/79 10/41 liv hpt e 28.3mg P<.0005 13.3mg 77.2mg 0/79 9/41 gal mix e 29.1mg P<.5 + 8.75mg n.s.s. 0/1 3/14 lun tum e no dre P=1. 92.8mg n.s.s. 0/100 0/44 tba mix e 6.04mg P<.0005 3.63mg 11.3mg 13/100 32/44 3789 H m syg wat 24m24 716 0 9.36mg liv mix e 7.55mg P<.0005 + 4.57mg 13.6mg 0/65 24/43 --- mhs e 12.7mg P<.002 + 6.13mg 41.1mg 0/16 10/26 liv hpt e 13.3mg P<.0005 7.35mg 27.4mg 0/65 16/43 bil mix e 19.7mg P<.007 + 8.45mg 218.mg 0/16 7/26 gal mix e 25.3mg P<.002 + 11.4mg 89.1mg 0/34 8/37 liv lcc e 30.0mg P<.0005 13.5mg 88.4mg 0/65 8/43 gal ppa e 42.5mg P<.01 16.1mg 1.95gm 0/34 5/37 lun tum e no dre P=1. 85.4mg n.s.s. 0/88 0/46 tba mix e 4.89mg P<.0005 3.04mg 8.58mg 7/88 34/46 3790 M f swa wat 65w73 1110 0 15.6mg 31.2mg Toth;jnci,60,201-204;1978 lun mix aes 6.44mg \ P<.0005 + 3.77mg 13.3mg 15/100 30/48 (9/37) liv mix aes 10.4mg * P<.0005 + 6.44mg 18.8mg 0/33 22/43 3/11 liv hpt aes 19.5mg * P<.0005 + 10.7mg 47.2mg 0/33 12/43 3/11 liv lcc aes 19.9mg \ P<.0005 + 9.67mg 59.0mg 0/33 10/43 (0/11) gal ade aes 31.5mg * P<.008 + 11.9mg 510.mg 0/29 4/23 1/5 3791 M f swa wat 23m23 1265 0 2.00mg 4.00mg Toth;nplm,27,25-31;1980 lun mix aes .921mg * P<.0005 + .636mg 1.37mg 15/99 39/49 47/50 blv mix aes 6.04mg * P<.0005 + 3.49mg 14.5mg 8/95 10/44 20/48 gal mix aes 57.9mg * P<.02 17.5mg n.s.s. 0/82 0/44 3/48 liv bhp aes 24.7mg * P<.2 4.02mg n.s.s. 0/32 1/10 0/5 3792 M f swa wat 23m24 1266 0 .500mg 1.00mg Toth;myco,78,11-16;1982a lun mix aes .745mg * P<.0005 + .444mg 1.77mg 29/94 31/48 32/48 lun adc aes 1.12mg * P<.0005 .665mg 2.72mg 14/94 23/48 22/48 lun ade aes 1.50mg * P<.002 .779mg 7.82mg 20/94 23/48 21/48 liv hpt aes 9.23mg * P<.2 - 2.27mg n.s.s. 0/50 2/23 0/17 liv agm aes 23.8mg * P<.5 - 4.03mg n.s.s. 3/77 1/45 3/38 3793 M f swa wat 92w92 1314 0 7.80mg Toth;myco,68,121-128;1979 lun mix es 2.16mg P<.0005 + 1.32mg 3.73mg 15/99 43/49 liv mix es 8.66mg P<.0005 + 4.95mg 17.1mg 0/68 18/47 blv mix es 12.2mg P<.0005 + 6.17mg 39.7mg 8/99 17/49 liv bhp es 17.5mg P<.0005 8.50mg 45.0mg 0/68 10/47 liv lcc es 22.4mg P<.0005 10.1mg 66.6mg 0/68 8/47 gal mix es 31.3mg P<.003 + 11.9mg 164.mg 0/63 5/40 gal ade es 39.7mg P<.006 13.7mg 449.mg 0/63 4/40 3794 M m swa wat 65w72 1110 0 13.0mg 26.0mg Toth;jnci,60,201-204;1978 liv mix aes 16.8mg \ P<.0005 + 8.19mg 48.2mg 1/81 11/47 (3/26) bil mix aes 36.2mg * P<.003 + 13.8mg 203.mg 0/75 5/29 0/8 gal ade aes 38.0mg \ P<.002 + 14.4mg 186.mg 0/81 5/47 (0/26) lun mix aes 14.2mg \ P<.02 + 6.00mg n.s.s. 22/98 20/47 (4/26) 3795 M m swa wat 22m23 1265 0 1.67mg 3.33mg Toth;nplm,27,25-31;1980 lun mix ae 1.72mg * P<.0005 + 1.12mg 3.09mg 22/98 36/49 31/46 blv mix ae 3.47mg \ P<.0005 + 1.64mg 14.5mg 5/78 13/42 (7/36) liv mix ae 5.47mg * P<.0005 + 3.10mg 12.2mg 2/78 6/42 14/36 gal mix ae 9.10mg * P<.0005 + 4.90mg 20.0mg 0/90 6/46 8/43 gal ade ae 9.88mg * P<.0005 5.21mg 22.8mg 0/90 6/46 7/43 3796 M m swa wat 23m24 1266 0 .417mg .833mg Toth;myco,78,11-16;1982a lun mix aes .865mg * P<.0005 + .488mg 2.69mg 19/83 27/45 24/47 lun ade aes 1.30mg * P<.002 .686mg 5.95mg 13/83 20/45 18/47 stg pla aes 3.43mg \ P<.01 - 1.04mg 215.mg 0/80 3/39 (0/43) lun adc aes 2.48mg * P<.03 1.08mg n.s.s. 9/83 14/45 11/47 sub fbs aes 2.60mg \ P<.02 - .916mg n.s.s. 1/83 5/45 (0/47) for sqp aes 11.2mg * P<.02 - 3.38mg n.s.s. 0/80 0/39 3/43 liv mix aes no dre P=1. 3.97mg n.s.s. 5/80 3/39 2/43 3797 M m swa wat 82w82 1314 0 6.50mg Toth;myco,68,121-128;1979 liv mix es 1.03mg P<.0005 + .527mg 1.99mg 1/69 28/30 lun mix es 1.87mg P<.0005 + 1.07mg 3.78mg 22/88 34/41 bil cho es 12.4mg P<.0005 + 5.05mg 44.5mg 0/69 6/30 gal ade es 15.2mg P<.0005 + 5.75mg 64.6mg 0/69 5/30 sev ade es 20.7mg P<.009 - 6.27mg 618.mg 0/51 3/24
See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.
A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.
For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.
The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.
A Supplementary Dataset gives details on dosing and survival for each experiment.
Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.
PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.